Investment
Features
FeesSafety
Academy
More
Pluang+

Pagaya Technologies posts record Q2 with 33% volume growth and 43% EBITDA rise, led by Auto segment.

Company Fundamentals
18 Sep 2026
Seeking Alpha
View Source
Bullish
Pagaya Technologies posts record Q2 with 33% volume growth and 43% EBITDA rise, led by Auto segment.

Pagaya Technologies Ltd. reported record Q2 2026 results, with Network Volume increasing 33%, revenue up 19%, and adjusted EBITDA rising 43%. The Auto segment drove over 75% of Network Volume growth, supported by major ABS and forward flow deals. The company's capital markets platform expanded with record ABS issuance and diversified funding, enabling scalable growth while reducing concentration risk. Despite strong profitability growth and attractive valuation multiples, credit and capital market cycles remain key risks to watch.

Pagaya Technologies' strong Q2 2026 results provide context for financial sector activity on Pluang. For readers following Financials-sector US stocks, here is Pluang's market snapshot as of Sep 18, 2026 19:02 WIB: out of 81 priced stocks, 27 rose and 48 fell. Notable movers include Deutsche Bank AG (DB) at USD 38.25 with a 2.05% decline, Robinhood Markets, Inc. (HOOD) at USD 111.97 gaining 1.97%, and Marathon Digital Holdings Inc (MARA) at USD 11.86 up 1.89%. Typical hold times range from 20 to 79 days, with strong buy-side order activity on DB, HOOD, and MARA.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App